BioNxt Solutions Secures Patent Acceptance from Eurasian Patent Organization

BioNxt Solutions Inc., a leader in bioscience specializing in advanced drug delivery systems, has achieved a milestone with the acceptance of its first national level patent by the Eurasian Patent Organization (EAPO). This approval affirms crucial patent claims such as novelty, inventive steps, and industrial applicability.

The flagship patent filing, reviewed positively by the European Patent Office in September 2024, covers sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases. It includes BioNxt's key product, BNT23001, a Cladribine formulation for multiple sclerosis.

The EAPO's jurisdiction spans eight nations, providing a unified patent process. BioNxt is progressing with patent nationalization in countries like the USA, Canada, and Japan to support its commercial strategy for treating autoimmune diseases.